Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin.

摘要

We studied the toxicity and antitumor activity of Liposomal-Annamycin in patients with metastatic breast carcinoma. Sixteen patients were treated. Toxicity was mild and consisted mostly of bone marrow suppression, particularly granulocytopenia. Non- hematological toxicity was less than what is usually seen with other anthracyclines. No responses were seen.